[A22-70] Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V
Last updated 02.02.2023
Commission awarded on 19.07.2022 by the Federal Joint Committee (G-BA).
Adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 with a CPS ≥ 1
- First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is a suitable therapy of physician’s choice: hint of major added benefit
- First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is no suitable therapy of physician’s choice: added benefit not proven
- Patients after first-line chemotherapy and for whom further antineoplastic therapy is an option: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.